Large-effect cognitive enhancement in healthy brains
Drugs or gene therapies that raise intelligence, learning rate or memory capacity in already-healthy people by a large, durable margin.
State of the art
Pooled meta-analysis of 47 studies gives modafinil SMD 0.12 and methylphenidate SMD 0.21 in healthy adults (Roberts et al. 2020); transgenic memory-enhanced rodents (NR2B, PDE inhibitors) show no human analogue.
- Trade-offs; manipulations that raise one capacity (plasticity, excitability) usually cost another, such as pain sensitivity or stability
- No molecular target identified that raises general cognitive capacity rather than arousal or motivation
- Healthy-subject ceiling effects and inverted-U dose dependence on baseline ability
- Measuring durable gain requires year-scale trials with no accepted endpoint
Who’s working on it
- Barbara SahakianResearcherDepartment of Psychiatry, University of Cambridge
Has run the longest-standing program of controlled trials of pharmacological cognitive enhancement in healthy volunteers, including the modafinil studies that anchor the current small effect-size estimates
- Amy ArnstenResearcherYale School of Medicine
Mapped the prefrontal catecholamine mechanisms that set working-memory capacity - the basis for guanfacine and for why dose-response curves in healthy brains are inverted-U rather than monotonic
- Michael KahanaResearcherUniversity of Pennsylvania
Showed closed-loop intracranial stimulation improving word recall in neurosurgical patients (2018), the largest verified memory-enhancement effect in humans to date
Acquired Tetra in 2020 and is running the PDE4D inhibitor zatolmilast in cognition trials for fragile X syndrome - the furthest-advanced small molecule aimed directly at a memory mechanism, though targeted at disease rather than healthy brains
- DARPA Restoring Active MemoryProgram
2014-2019 program that funded implanted memory-prosthesis work, including the Penn closed-loop stimulation trials; the main government attempt at large-effect human memory enhancement
- IARPA SHARPProgram
Strengthening Human Adaptive Reasoning and Problem-solving (2015-2019) tested interventions to raise reasoning in healthy adults and found no large durable pharmacological effect
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| research | Target discovery from human cognitive genetics plus long-duration healthy-volunteer trials with pre-registered cognitive endpoints | $$$ $100M – $1B |
Depends on
Required by
No other capability builds on this directly.